Brokers Issue Forecasts for LSTA Q1 Earnings

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Equities research analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for Lisata Therapeutics in a research report issued to clients and investors on Wednesday, October 30th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings of ($0.74) per share for the quarter. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.97) per share. Brookline Capital Management also issued estimates for Lisata Therapeutics’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.78) EPS and Q4 2025 earnings at ($0.75) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Lisata Therapeutics in a research report on Wednesday, September 18th.

Lisata Therapeutics Stock Up 0.7 %

LSTA opened at $2.83 on Thursday. Lisata Therapeutics has a twelve month low of $2.02 and a twelve month high of $3.83. The company has a 50-day simple moving average of $2.96 and a 200 day simple moving average of $3.08. The stock has a market capitalization of $23.55 million, a price-to-earnings ratio of -1.10 and a beta of 1.21.

Lisata Therapeutics (NASDAQ:LSTA) last announced its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.14. During the same quarter in the prior year, the firm posted ($0.50) earnings per share.

Institutional Investors Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP increased its position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.